|abstract||Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease|
|type of project||clinical studies|
|status||ongoing - follow up|
|start of project||2020|
|end of project||2022|
Prospective, multi-center, open-label, single-arm registry designed
enroll 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR) allcomer patients with coronary artery disease in around 25 sites in 3
European countries (Switzerland, Germany & France).
Patients will receive at least one Supraflex Cruz™ sirolimus-eluting stent as per current practice and will be followed up for 12 months.
|responsible person||Dr. Daniel Weilenmann|